Mayne Pharma Group Aktie
| 2,58EUR | -0,12EUR | -4,44% |
WKN DE: A1C821 / ISIN: AU000000MYX0
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 76,06 |
| Government Pension Fund - Global (The) | 17,23 |
| Viburnum Funds Pty Ltd. | 7,15 |
| Bruce L. Mathieson | 6,22 |
| Bmgbj Myx Pty Ltd. | 6,09 |
| Rubric Capital Management LP | 5,12 |
| Lazard Asset Management Pacific Co. | 4,98 |
| Mithra Pharmaceuticals SA | 4,96 |
| MLC Investments Ltd. | 4,08 |
| Gft 2 Co. Pty Ltd. | 1,52 |
| Vanguard Australian Shares Index Fund | 1,36 |
| Vanguard Total International Stock Index Fund | 1,35 |
| Ivl Group Ltd. | 0,94 |
| Vivnat (Curtin) Pty Ltd. | 0,88 |
| Investors Mutual Future Leaders Fund | 0,80 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 900 | 900 | 0 | 0 | 0 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,51 | 0,45 | 0,00 | 0,00 | 0,00 |
Bilanz (in Mio. AUD) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 491 | 417 | 512 | 554 | 461 |
| Summe Anlagevermögen | 1 351 | 1 062 | 791 | 695 | 683 |
| Summe Aktiva | 1 842 | 1 478 | 1 303 | 1 248 | 1 143 |
Bilanz (in Mio. AUD) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 398 | 347 | 414 | 48 | 39 |
| Summe Fremdkapital | 800 | 707 | 746 | 614 | 689 |
| Summe Eigenkapital | 1 042 | 772 | 557 | 634 | 454 |
| Summe Passiva | 1 842 | 1 478 | 1 303 | 1 248 | 1 143 |
Adresse
| 1538 Main North Road, 5106 Salisbury | |
| Telefon | +61 (8) 8209-2666 |
| Fax | +61 (8) 8281-0284 |
| Internet | http://www.maynepharma.com |
Management
|
Aaron Gray
Chief Financial Officer |
|
Ann Custin
Non-Executive Director |
|
Anne Lockwood
Non-Executive Director |
|
Brant Schofield
Executive Vice President-Corporate Development |
|
Bruce G. Robinson
Independent Non-Executive Director |
|
David Petrie
Non-Executive Director |
|
Erinn Nathaniel
Director-Human Resources |
|
Frank C. Condella
Chairman |
|
Frank Casty
Chief Medical Officer & EVP |
|
Kathryn MacFarlane
Non-Executive Director |
|
Keith Moore
Vice President-Research & Development |
|
Kimberly Parker
Executive Vice President & General Counsel |
|
Laura Loftus
Secretary & Associate General Counsel |
|
Patrick J. Blake
Independent Non-Executive Director |
|
Richard Moldin
President-Generics Products Division |
|
Shawn Patrick O'Brien
Chief Executive Officer, Director & MD |
|
Thomas Duthy
Investor Relation Contact |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
